Skin, Hair & Aesthetic
GHK-Cu FDA Status for Clinics
Regulatory Guidance & Legal Compliance for Licensed Practitioners
Skin, hair and aesthetic peptide protocols sit in a different clinical space from gut health or tissue repair. The target is chronic, age-related change in skin quality rather than inflammatory disease or acute injury, which alters the timeline, the outcome measures and the evidence a clinic can reasonably expect to find. This page documents where the substances most discussed in this category stood when we reviewed the federal record in September 2026. One of them has an unusual regulatory position that turns entirely on route of administration, and that distinction is the most important thing on the page.
How We Work:
Phoenix Meds Inc. is a peptide sourcing coordinator for licensed clinics. We coordinate sourcing where we can identify an applicable regulatory basis and provide regulatory documentation where we cannot. Each preparation is reviewed on its own record. For the statutory framework, the criteria under sections 503A and 503B, research-use-only labelling, enforcement risk and our partner model, see how the compounding rules work. This page covers only what applies to the aesthetic category.
HOW WE SUPPORT CLINICS
Phoenix Meds Regulatory Support Model
Aesthetic sourcing questions rarely turn on whether a substance is approved. They turn on route of administration and on what is actually inside a branded blend. Our support in this category is built around those two problems.
Status Tracked by Route
GHK-Cu’s position differs by route, and FDA’s own list draws that line explicitly. We track topical and injectable separately, because a supplier quote that does not name the route leaves the central question open.
Blend Composition Review
KLOW, GLOW, FOY and similar preparations are trade names, not characterised substances. We work through the component list with you and check each ingredient separately, because that is the only way a blend can be assessed at all.
Statutory Criteria Applied per Component
The three conditions under section 503A, and the separate conditions under 503B, applied to each ingredient rather than to the product name. Every constituent substance has to be assessed on its own, alongside the requirements that apply to the finished preparation.
Enforcement Risk, Explained
Aesthetic practices sit in a different enforcement position from medical clinics: state boards, cosmetic advertising rules and medspa supervision requirements all apply on top of federal law. We set that out so your own counsel can assess it. We are not lawyers and this is not a legal opinion.
Pharmacy Partner Network
Monitoring, With a Date in the Diary
GHK-Cu remains under evaluation. FDA’s May 14, 2026 document lists GHK-Cu, except for injectable routes, in Category 1 and says the agency intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. We track the nominations list, both Bulks Lists and Federal Register notices, and re-date this page when anything moves.
Critical Note for this Category
Based on the federal sources reviewed in September 2026, we did not identify an applicable 503A or 503B basis for compounding injectable GHK-Cu from bulk. We document that finding before any sourcing discussion. A supplier relying on a different basis should be able to identify the supporting federal record. Clinics exploring these preparations should do so with qualified legal counsel.
Clinic Benefits
What an aesthetic practice actually gets from working with us on this category.
✓ The Route Question, Answered
A straight answer on whether a given form of GHK-Cu sits inside FDA’s enforcement discretion or outside it, with the list entry quoted rather than paraphrased.
✓ Blend Transparency
Help obtaining a written component list from a supplier, and an ingredient-by-ingredient assessment once you have it. No blend can be judged from its trade name.
✓ Cosmetic Claim Awareness
Aesthetic marketing carries advertising exposure that clinical practice does not. We flag where a protocol description crosses from what was studied into what is claimed.
✓ Documentation Support
Help building a compliance file that records what you verified, when, and against which source — the record that matters if anyone asks later.
✓ Supplier Vetting
For preparations where we identify an applicable pathway, we review supplier and facility credentials alongside the product-specific regulatory record. Credentials alone do not establish that a particular bulk substance may be used in compounding.
✓ Counsel Ready
The regulatory position organised so your attorney can assess it in an hour rather than rebuilding the research from scratch.
Aesthetic Practice and the Evidence It Works With
Aesthetic practitioners work toward measurable change in the appearance and properties of skin and hair rather than treatment of disease. That shapes the evidence framework: outcomes are gradual, partly subjective, and difficult to separate from ordinary variation without objective measurement over months.
Practitioners in dermatology, aesthetics and age-management medicine have explored peptide approaches on the strength of preclinical work on fibroblast activity and collagen synthesis. Clinical judgment is a separate question from whether an applicable regulatory pathway exists for the preparation being considered.
Route of administration decides the answer here
For GHK-Cu, route of administration is material to FDA’s current treatment of the substance. Any supplier conversation that does not begin with the route is not answering the question you asked.
The Substances Discussed in This Category
GHK-Cu (Copper Peptide Complex)
What it is: Copper bound to the tripeptide glycyl-L-histidyl-L-lysine, with a long history of use in topical cosmetic products.
Research context: Preclinical work covers collagen synthesis, fibroblast activity and dermal matrix composition across several skin models, with proposed activity through TGF-β pathways. Human clinical evidence for aesthetic endpoints is limited, and the topical cosmetic record does not carry over to injection: route, dose and systemic exposure all differ. Published work describes mechanism. It does not establish aesthetic outcomes in humans for injected material.
Regulatory position: FDA sorts nominated bulk substances into three categories while it reviews them. Category 1 covers substances not identified as presenting significant safety risks, where FDA exercises enforcement discretion during review. Category 2 covers substances FDA has flagged for safety risks. Neither category is the 503A Bulks List. Under section 503A, the bulk-substance condition can also be satisfied through an applicable USP/NF monograph or by use of a substance that is a component of an FDA-approved drug product.
GHK-Cu was removed from Category 1 on April 22, 2026 after its nominations were withdrawn. FDA says that on May 5 one nominator clarified that only the injectable route was being withdrawn. FDA’s May 14 document now lists ‘GHK-Cu (except for injectable routes of administration)’ in Category 1. Injectable use remains outside that entry. The entry reads “GHK-Cu (except for injectable routes of administration).”
Category 1 is not approval and it is not inclusion on the 503A Bulks List. FDA’s interim policy states that it does not intend to take action against a compounder using a Category 1 substance when the conditions in its guidance are met. GHK-Cu does not appear on the 503A Bulks List.
Injectable GHK-Cu falls outside the Category 1 entry. It appears on neither the 503A nor the 503B Bulks List. On the sources we reviewed in August 2026 we did not identify an FDA-approved drug product containing it, or an applicable USP or NF monograph. Based on the federal sources reviewed in September 2026, we did not identify an applicable 503A or 503B basis for compounding injectable GHK-Cu from bulk. It is the form used in the blends described below.
Fountain of Youth (FOY)
What it is: A trade name, not a substance. Preparations sold under it are multi-peptide formulations for aesthetic use, and nothing standardises them, so composition can differ between suppliers and between lots.
Research context: No published human clinical evidence examines FOY as a formulation. The literature on individual component peptides describes mechanisms studied in preclinical models, and those findings do not transfer to a combination: a blend’s effects are not the sum of its components studied separately.
Regulatory position: FDA’s bulk-substance framework operates substance by substance, against specific nominated uses, so no FDA determination attaches to a product name. The analysis starts from the identity, route and intended use of each component, and any component that does not qualify has to be resolved before the finished preparation can be considered under that framework.
That puts the first step with the supplier: without a written component list, there is nothing to assess. Once the components are known, each is checked against the conditions under section 503A, and separately under 503B. Where formulations of this type contain injectable GHK-Cu, BPC-157, TB-500 or KPV, our September 2026 review did not identify an applicable 503A or 503B bulk-compounding basis for those components.
Named Multi-Peptide Blends: KLOW, GLOW and Similar Formulations
Blends circulate under trade names rather than substance names. KLOW is sold as a four-peptide combination of GHK-Cu, BPC-157, TB-500 and KPV. GLOW is sold as a three-peptide version of the same idea, without KPV.
The naming matters for a reason that is easy to miss. FDA’s framework operates one bulk substance at a time, against a specific nominated use, so no FDA determination attaches to a blend’s trade name. Because the name establishes nothing on its own, a supplier should be able to identify the formulation’s ingredients, the route, and the legal basis they rely on for compounding or supplying it.
The rule that governs every combination
Combining substances into one preparation does not remove the need to evaluate each constituent substance, and the finished formulation, under the applicable federal and state requirements. If a required component does not qualify under the framework being relied on, that has to be resolved before the finished formulation can be considered eligible under it. Combination does not average the components’ status and does not create a new one.
Component status as of September 2026
GHK-Cu. Category 1 applies to non-injectable routes only, as set out above. Since KLOW and GLOW are injectable preparations, the GHK-Cu in them falls outside even that enforcement discretion.
BPC-157, TB-500 and KPV. None appears on the 503A Bulks List or the 503B Bulks List. On the sources we reviewed in September 2026, we did not identify an FDA-approved drug product containing any of them as a component, or an applicable USP or NF monograph. All three were considered by the Pharmacy Compounding Advisory Committee on 23 July 2026. FDA’s briefing materials set out the agency’s evaluation and recommended against inclusion in each case; the committee’s votes went the other way by narrow margins, as reported by trade press covering the meeting. Those votes are advisory and did not change the federal compounding framework. No rulemaking has followed.
What that adds up to
Each component has to satisfy the requirements that apply to the framework being relied on. Based on the federal sources reviewed in September 2026, we did not identify an applicable 503A or 503B basis for the injectable KLOW or GLOW formulations described here.
One further point worth raising with any supplier. FDA assessed these substances against particular nominated uses: ulcerative colitis for BPC-157, wound healing for TB-500 and for KPV. Aesthetic and cosmetic use was not the question in front of the agency for any of them. FDA evaluated BPC-157 for ulcerative colitis, TB-500 for wound healing, and KPV for wound healing and inflammatory conditions. Those were not aesthetic uses. FDA staff recommended against inclusion, while the advisory committee later recommended inclusion. Neither event changed the 503A Bulks List.
Regulatory status current as of September 2026.
For the injectable preparations on this page, we have not identified any basis on which a pharmacy or outsourcing facility could compound them under sections 503A or 503B. Compounding from a bulk drug substance is permitted only when the applicable statutory and regulatory requirements are satisfied; based on the sources we reviewed, we have not identified such a pathway here. That is not the same as a ban: the absence of a compounding pathway does not mean these substances are federally scheduled or controlled, and separate federal and state requirements may still apply. Non-injectable GHK-Cu is a different case, and FDA Category 1 status does not itself constitute approval or authorization to compound.
The Current Evidence Position
The topical cosmetic literature on copper peptides is long-standing and reasonably substantial. That is not the same body of evidence as the one a clinic needs when considering an injected preparation, and the distinction gets lost more often than any other point in this category.
For injected GHK-Cu in aesthetic indications, and for multi-peptide blends of any composition, we have not identified a completed controlled trial establishing outcomes in humans. Registry records change, so check ClinicalTrials.gov directly rather than relying on any secondhand summary, including this one. This means that:
- Safety of injected material at aesthetic dosing is not characterised in humans.
- Effective dose ranges for cosmetic endpoints are not established by trial.
- Candidate patients, contraindications and objective outcome measures are not defined.
- Durability after a protocol ends is not documented.
- For blends, no evidence addresses the combination at all — only its parts, separately, in preclinical models.
The evidence described above does not establish an evidence-based clinical protocol for the injectable preparations discussed here. Clinical decisions and standards of care are separate from the compounding analysis on this page.
Why Clinics Have Explored Aesthetic Peptides
Despite the regulatory and evidence limitations set out above, these preparations have gained attention in aesthetic settings because:
- The topical record creates an assumption. Copper peptides have a long cosmetic history, and that familiarity transfers to injection in practitioners’ minds more readily than the evidence supports.
- Interest often begins when patients or clinicians look beyond established aesthetic options. That interest does not establish efficacy or regulatory eligibility.
- Off-label prescribing is familiar territory. Practitioners are used to broad discretion in prescribing approved drugs off-label. Off-label prescribing authority does not itself create a federal compounding pathway for a bulk drug substance. The two questions are commonly, and incorrectly, treated as one.
- Patient demand is real. Patients encounter these preparations in cosmetic and wellness media and ask about them directly.
None of the above is a recommendation to use these compounds. We do not coordinate a preparation where we have not identified an applicable regulatory basis, and this page exists so a clinic can see the whole position and hand it to counsel before a supplier quotes a price.
Two Questions Specific to This Category
Our regulatory overview sets out the general supplier checks that apply to every peptide: statutory criteria, pharmacy credentials, research-use-only labelling and documentation. Two questions matter here that do not arise elsewhere.
Ask about the route before anything else
For GHK-Cu, the route decides the regulatory answer. A supplier quoting “GHK-Cu” without specifying the form is answering a different question from the one you asked. Enforcement discretion under Category 1 covers non-injectable routes only, and it is discretion rather than authorisation in either case. If a quote arrives for injectable material on the strength of Category 1 status, that is a misreading of a list entry which expressly excludes injection.
Get the component list for any blend, in writing
You cannot assess KLOW, GLOW, FOY or any proprietary formulation without knowing exactly what is in it and at what strength. There is no FDA determination about a blend to fall back on, so the components are the only basis for an answer. A supplier unwilling to put the composition in writing has answered the only question that matters.
Regulatory Position and Phoenix Meds Coordination Policy
We do not currently coordinate pharmacy sourcing for the injectable GHK-Cu preparations or branded GHK-Cu blends discussed on this page where we have not identified an applicable federal compounding pathway.
Our sourcing coordination is based on the regulatory pathway applicable to the specific preparation and pharmacy involved. Where we cannot identify that basis from the current record, we do not represent the preparation as eligible under section 503A or 503B.
For GHK-Cu, our current support focuses on regulatory review, sourcing documentation, and compliance coordination so that clinic partners can make informed decisions with their pharmacy and qualified legal or regulatory counsel.
We keep this page updated because there is still a lot of confusion around the regulatory status of these peptides. Our role is to look at the actual FDA record, check the status of a preparation by route, review the ingredients in a blend, and compare supplier claims with the underlying documentation. We can also help organize the compliance file for review by your legal or regulatory counsel. More detail on how we approach this is available in our guide to the compounding framework.
If FDA changes the applicable Bulks List, opens a relevant rulemaking, or issues new information that changes the regulatory picture for these substances, we will review the change and update this page.
Verify This Yourself
FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated 14 May 2026 — the GHK-Cu Category 1 entry and its injectable carve-out
Orrick — the April 2026 removals and the planned PCAC consultation on GHK-Cu
21 CFR 216.23 — the 503A Bulks List: six substances, no peptides
FDA — 503B Bulk Drug Substances List — five substances, no peptides
FDA — PCAC meeting, 23–24 July 2026 — the BPC-157, KPV and TB-500 reviews and their nominated uses
Related Clinic Resources
Choosing a Reliable Injectable Supplier
Vetting framework for any injectable supplier, with emphasis on statutory criteria and documentation.
Legal & Regulatory Status Overview
The statutory framework, criteria under 503A and 503B, enforcement risk and supplier due diligence across every category.
Medical Supply Chain Compliance
Documentation requirements, supplier vetting and regulatory due diligence across all therapeutic categories.
Storage and Handling of Lyophilized Peptides
Maintaining peptide integrity from arrival through reconstitution and administration.
Gut Health & Inflammatory Peptides
BPC-157 and KPV: FDA status, statutory criteria and supplier verification.
Injury Recovery & Tissue Repair
BPC-157 and TB-500 for acute injury and post-surgical recovery, with current regulatory position.
Disclaimer and regulatory scope:
This page is regulatory information for licensed clinics, compiled from public FDA materials. It is not medical or legal advice, and not a determination that any product or preparation is lawful.
On the federal sources reviewed in September 2026 we did not identify a 503A or 503B basis permitting injectable GHK-Cu, KLOW or GLOW to be compounded from bulk. On the federal sources reviewed in September 2026, we did not identify an applicable 503A or 503B basis for compounding injectable GHK-Cu, KLOW or GLOW from bulk. FDA’s May 14, 2026 503A nominations document lists ‘GHK-Cu (except for injectable routes of administration)’ in Category 1. Category 1 is an interim enforcement policy subject to FDA’s stated conditions; it is not FDA approval and it is not inclusion on the 503A Bulks List. These are our findings from the cited federal record, not a legal determination for a particular transaction.
State pharmacy law and medical practice acts apply on top. For how 503A and 503B differ and what the bulks lists are, see our Legal & Regulatory Status Overview. Work with counsel in your state.
Phoenix Meds Inc. is not a pharmacy, clinic, prescriber or medical provider, and we do not dispense. We coordinate sourcing between licensed clinics and licensed pharmacies. The pharmacy or outsourcing facility prepares, dispenses and ships; any clinical decision rests with the prescriber. Last reviewed: September 2026.